Abstract
Background: International guidelines recommend the use of angiotensin-converting enzyme inhibitors, possibly in combination with other antihypertensive drugs, to treat hypertension with associated risk factors.
Objective: The aim of this study was to compare the antihypertensive effect of the combination of zofenopril plus hydrochlorothiazide versus zofenopril monotherapy in patients with essential hypertension, according to their cardiovascular risk level.
Methods: This was a post hoc analysis of a previously published efficacy and tolerability study. After a 4-week placebo washout, patients with mild to moderate essential hypertension (diastolic blood pressure [DBP] 95-115 mm Hg), aged 18 to 75 years, were randomized at a ratio of 2:1:1 to treatment with zofenopril 30 mg plus hydrochlorothiazide 12.5 mg or monotherapy with zofenopril 30 mg or hydrochlorothiazide 12.5 mg for 12 weeks in an international, multicenter, double-blind study. This period was followed by 24 weeks of open-label treatment. Systolic BP [SBP] and DBP were measured by mercury sphygmomanometry, and changes associated with treatment were calculated. Patients' cardiovascular risk was computed using the Heart Score algorithm. Patients were classified in quartiles according to distribution of cardiovascular risk level, and comparisons were limited to the zofenopril plus hydrochlorothiazide and zofenopril monotherapy treatment groups. The primary end point was change in office DBP.
Results: Two hundred forty-six patients (139 men, 107 women; mean [SD] age, 54 [11] years) were included in the analysis. Mean baseline cardiovascular risk was similar in the zofenopril plus hydrochlorothiazide group and the zofenopril monotherapy group (7% vs 9%). DBP and SBP reductions with treatment were significantly greater (both, P < 0.01) with combination treatment than with monotherapy for each quartile of cardiovascular risk. Cardiovascular risk reduction at the end of the 12 weeks of double-blind treatment was greater in the zofenopril plus hydrochlorothiazide group than in the zofenopril monotherapy group (1.9% vs 0.2%; P < 0.01), particularly in the group of patients with the highest cardiovascular risk at baseline (5.2% vs 2.0%). At the end of the 24-week open-label treatment period, the mean reduction in cardiovascular risk was also significantly greater in the combination treatment group than in the monotherapy group (1.4% vs 0.5%; P < 0.01).
Conclusions: In these hypertensive patients, combination treatment with zofenopril plus hydrochlorothiazide was associated with a significantly greater decrease in BP compared with zofenopril monotherapy, regardless of the patient's cardiovascular risk. The difference between combination treatment and monotherapy was particularly evident for the group of patients at highest risk.
Key words: essential hypertension, cardiovascular risk, zofenopril, hydrochlorothiazide
Full Text
The Full Text of this article is available as a PDF (627.6 KB).
References
- 1.Mancia G, De Backer G, Dominiczak A, for the Management of Arterial Hypertension of the European Society of Hypertension and the European Society of Cardiology 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) J Hypertens. 2007;25:1105–1187. doi: 10.1097/HJH.0b013e3281fc975a. [published correction appears in J Hypertens. 2007;25:1749] [DOI] [PubMed] [Google Scholar]
- 2.Chobanian AV, Bakris GL, Black HR, for the National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure and the National High Blood Pressure Education Program Coordinating Committee The seventh report of the joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: JNC 7 report. JAMA. 2003;289:2560–2572. doi: 10.1001/jama.289.19.2560. [published correction appears in JAMA. 2003;290:197] [DOI] [PubMed] [Google Scholar]
- 3.Moser M, Setaro JF. Clinical practice. Resistant or difficult-to-control hypertension. N Engl J Med. 2006;355:385–392. doi: 10.1056/NEJMcp041698. [DOI] [PubMed] [Google Scholar]
- 4.Pasini AF, Garbin U, Nava MC. Effect of sulfhydryl and non-sulfhydryl angiotensinconverting enzyme inhibitors on endothelial function in essential hypertensive patients. Am J Hypertens. 2007;20:443–450. doi: 10.1016/j.amjhyper.2006.09.020. [DOI] [PubMed] [Google Scholar]
- 5.Evangelista S, Manzini S. Antioxidant and card ioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenopril. J Int Med Res. 2005;33:42–54. doi: 10.1177/147323000503300103. [DOI] [PubMed] [Google Scholar]
- 6.Altunoluk B, Soylemez H, Oguz F. An angiotensin-converting enzyme inhibitor, zofenopril, prevents renal ischemia/reperfusion injury in rats. Ann Clin Lab Sci. 2006;36:326–332. [PubMed] [Google Scholar]
- 7.Napoli C, Sica V, de Nigris F. Sulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertension. Am Heart J. 2004;148:e5. doi: 10.1016/j.ahj.2004.03.025. [DOI] [PubMed] [Google Scholar]
- 8.Borghi C, Ambrosioni E, for the Survival of Myocardial Infarction Long-term Evaluation-2 Working Party Double-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: Results of the Survival of Myocardial Infarction Long-term Evaluation-2 (SMILE-2) study. Am Heart J. 2003;145:80–87. doi: 10.1067/mhj.2003.24. [DOI] [PubMed] [Google Scholar]
- 9.Borghi C, Bacchelli S, Esposti DD, for the SMILE Study Investigators Effects of the administration of an angiotensin-converting enzyme inhibitor during the acute phase of myocardial infarction in patients with arterial hypertension. Survival of Myocardial Infarction Longterm Evaluation. Am J Hypertens. 1999;12:665–672. doi: 10.1016/s0895-7061(99)00042-4. [DOI] [PubMed] [Google Scholar]
- 10.Borghi C, Bacchelli S, Esposti DD, Ambrosioni E, for the SMILE Study Effects of the early ACE inhibition in diabetic nonthrombolyzed patients with anterior acute myocardial infarction. Diabetes Care. 2003;26:1862–1868. doi: 10.2337/diacare.26.6.1862. [DOI] [PubMed] [Google Scholar]
- 11.Kelbaek H, Agner E, Wroblewski H. Angiotensin converting enzyme inhibition at rest and during exercise in congestive heart failure. Eur Heart J. 1993;14:692–695. doi: 10.1093/eurheartj/14.5.692. [DOI] [PubMed] [Google Scholar]
- 12.Binkley PF, Haas GJ, Starling RC. Sustained augmentation of parasympathetic tone with angiotensin-converting enzyme inhibition in patients with congestive heart failure. J Am Coll Cardiol. 1993;21:655–661. doi: 10.1016/0735-1097(93)90098-l. [DOI] [PubMed] [Google Scholar]
- 13.Elijovich F, Laffer CL, Schiffrin EL. The effects of atenolol and zofenopril on plasma atrial natriuretic peptide are due to their interactions with target organ damage of essential hypertensive patients. J Hum Hypertens. 1997;11:313–319. doi: 10.1038/sj.jhh.1000438. [DOI] [PubMed] [Google Scholar]
- 14.Leonetti G, Rappelli A, Omboni S. A similar 24-h blood pressure control is obtained by zofenopril and candesartan in primary hypertensive patients. Blood Press. 2006;15:18–26. [Google Scholar]
- 15.Lacourcière Y, Provencher P. Comparative effects of zofenopril and hydrochlorothiazide on office and ambulatory blood pressures in mild to moderate essential hypertension. BrJ Clin Pharmacol. 1989;27:371–376. doi: 10.1111/j.1365-2125.1989.tb05379.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 16.Malacco E, Piazza S, Omboni S, for the Zofenopril Study Group Zofenopril versus lisinopril in the treatment of essential hypertension in elderly patients: A randomised, double-blind, multicentre study. Clin Drug Investig. 2005;25:175–182. doi: 10.2165/00044011-200525030-00003. [DOI] [PubMed] [Google Scholar]
- 17.Parati G, Omboni S, Malacco E. Antihypertensive efficacy of zofenopril and hydrochlorothiazide combination on ambulatory blood pressure. Blood Press. 2006;15:7–17. [Google Scholar]
- 18.Zanchetti A, Parati G, Malacco E. Zofenopril plus hydrochlorothiazide: Combination therapy for the treatment of mild to moderate hypertension. Drugs. 2006;66:1107–1115. doi: 10.2165/00003495-200666080-00006. [DOI] [PubMed] [Google Scholar]
- 19.Malacco E, Omboni S. Anti hypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrome. Adv Ther. 2007;24:1006–1015. doi: 10.1007/BF02877705. [DOI] [PubMed] [Google Scholar]
- 20.Conroy RM, Pyorala K, Fitzgerald AP, for the SCORE Project Group Estimation of ten-year risk of fatal cardiovascular disease in Europe: The SCORE project. Eur Heart J. 2003;24:987–1003. doi: 10.1016/s0195-668x(03)00114-3. [DOI] [PubMed] [Google Scholar]
- 21.Julius S, Kjeldsen SE, Weber M, for the VALUE Trial Group Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomised trial. Lancet. 2004;363:2022–2031. doi: 10.1016/S0140-6736(04)16451-9. [DOI] [PubMed] [Google Scholar]
- 22.Black HR, Elliott WJ, Grandits G, for the CONVINCE Research Group Principal results of the Controlled Onset Verapamil Investigation of Cardiovascular End Points (CONVINCE) trial. JAMA. 2003;289:2073–2082. doi: 10.1001/jama.289.16.2073. [DOI] [PubMed] [Google Scholar]
- 23.ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) JAMA. 2002;288:2981–2997. doi: 10.1001/jama.288.23.2981. [published corrections appear in JAMA. 2003;289:178 and JAMA. 2004;291:2196] [DOI] [PubMed] [Google Scholar]
- 24.Ambrosioni E. Defining the role of zofenopril in the management of hypertension and ischemic heart disorders. Am J Cardiovasc Drugs. 2007;7:17–24. doi: 10.2165/00129784-200707010-00002. [DOI] [PubMed] [Google Scholar]